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Abstract
Tumor-associated macrophages are involved in angiogenesis and tumor progression, but their role and specific
site of action in prostate cancer remain unknown. To explore this, Dunning R-3327 AT-1 rat prostate tumor cells
were injected into the prostate of syngenic and immunocompetent Copenhagen rats and analyzed at different time
points for vascular proliferation and macrophage density. Endothelial proliferation increased with tumor size both
in the tumor and importantly also in the extratumoral normal prostate tissue. Macrophages accumulated in the
tumor and in the extratumoral normal prostate tissue and were most abundant in the invasive zone. Moreover,
only extratumoral macrophages showed strong positive associations with tumor size and extratumoral vascular
proliferation. Treatment with clodronate-encapsulated liposomes reduced the monocyte/macrophage infiltration
and resulted in a significant inhibition of tumor growth. This was accompanied by a suppressed proliferation in
microvessels and in the extratumoral prostate tissue also in arterioles and venules. The AT-1 tumors produced, as
examined by RT2 Profiler PCR arrays, numerous factors promoting monocyte recruitment, angiogenesis, and tis-
sue remodeling. Several, namely, chemokine (C-C) ligand 2, fibroblast growth factor 2, matrix metalloproteinase 9,
interleukin 1β, interferon γ, and transforming growth factor β, were highly upregulated by the tumor in vivo com-
pared with tumor cells in vitro, suggesting macrophages as a plausible source. In conclusion, we here show the
importance of extratumoral monocytes/macrophages for prostate tumor growth, angiogenesis, and extratumoral
arteriogenesis. Our findings identify tumor-associated macrophages and several chemotactic and angiogenic fac-
tors as potential targets for prostate cancer therapy.
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Introduction
The tumor microenvironment contains many different cell types,
such as fibroblasts, myofibroblasts, adipocytes, blood, and lymph ves-
sels, and a wide range of leukocytes that can all influence tumor pro-
gression. Tumor-associated macrophages (TAMs) are the major
component of the leukocyte infiltrate, and increased intratumoral
macrophage density correlates with poor prognosis in more than
80% of published studies [1]. Numerous factors recruit peripheral
blood monocytes from the circulation providing the tumor with a
constant supply of TAMs, and accumulating evidence suggests that
tumors exploit macrophages for their own benefit. For example,
TAMs can promote angiogenesis by secreting proangiogenic factors
and facilitate invasion by releasing matrix-degrading enzymes [1–5].
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Studies of macrophage infiltration to human prostate cancer, how-
ever, show diverse results with both positive and negative association
to clinical outcome and cancer progression [6,7]. In a subcutaneous
human prostate xenograft model in immune-compromised mice, in-
hibition of a potent monocyte recruitment factor, monocyte chemo-
attractant protein 1/chemokine (C-C) ligand 2 (MCP-1/CCL-2),
results in reduced macrophage infiltration, angiogenesis, and tumor
growth [8], but as CCL-2 also influences tumor and endothelial cells
directly, the effects could be multiple.
To elucidate this further, and to mimic the natural tumor environ-
ment in patients, we have used a rat prostate tumor model where a
small number of Dunning R-3327 AT-1 rat prostate tumor cells are
injected into the ventral prostate of immunocompetent and syngenic
rats [9]. The tumor cells rapidly establish tumors located within a
normal prostate and host environment. Our previous study showed
that vascular density increase with tumor growth both in the tumor
and importantly also in the surrounding normal prostate [9]. This is
of significance because extratumoral vessels secure blood supply to
and drainage from the tumor and manipulation of these vessels im-
paired tumor growth [9,10]. To reduce macrophage infiltration to
the tumor and its surroundings, we now used intraperitoneal injec-
tions of clodronate (dichloromethylene-bisphosphonate)-encapsulated
liposomes designed to target phagocytic cells. After internalization
and release of free clodronate, macrophages die through apoptosis
[11]. Tumors from clodronate-liposome–treated rats were compared
with controls with regard to tumor weight, intratumoral and extratu-
moral macrophage content, and vascularity. In addition, the angiogenic
and chemotactic profiles of the AT-1 orthotopic tumor were examined.
Here, we show the importance of macrophages to stimulate extra-
tumoral vascular growth and thereby create a microenvironment nec-
essary for subsequent tumor growth. Furthermore, we demonstrate
that the tumor expresses multiple factors that could stimulate mono-
cyte recruitment and angiogenesis and could induce tissue remodeling.
Our findings identify TAMs and several chemotactic and angiogenic
factors as potential therapeutic targets for prostate cancer.
Materials and Methods
Orthotopic Implantation of Dunning R-3327
Rat AT-1 Tumor Cells
Rat prostate AT-1 tumor cells (kindly donated by Dr J.T. Isaacs,
John Hopkins, Baltimore, MD) were grown in culture as previously
described [12].
For morphologic analysis, AT-1 cells (2 × 103 cells in 50 μl of
RPMI 1640) were carefully injected into one lobe of the ventral pros-
tate of adult Copenhagen rats (Charles River, Sulzfeld, Germany) as
previously described [9]. Rats were killed at 7 (n = 6), 10 (n = 16),
and 14 days (n = 11) after tumor cell injection. At sacrifice, the animals
were injected with bromodeoxyuridine (BrdU, 50 mg/kg; Sigma-
Aldrich, Oslo, Norway), and the prostate tissue was removed, weighed,
and prepared as described earlier [9,13].
For RNA preparation, AT-1 cells were injected in the same way
(n = 11). Animals injected with vehicle (50 μl of RPMI, n = 10) were
used as controls. After 10 days, the animals were killed and the VP
lobes were quickly removed, frozen in liquid nitrogen, and stored at
−80°C. All of the animal work was approved by the local ethical com-
mittee for animal research.
Factor VIII, CD68, and BrdU
Sections, 5-μm thick, were immunostained using primary antibo-
dies against CD68 (AbD Serotec, Oxford, UK), factor VIII (Dako,
Stockholm, Sweden), and BrdU (Dako) as described earlier [13–15].
The percentage of factor VIII–stained blood vessels, CD68-positive
macrophages, and BrdU-positive proliferating tumor cells and the
number of BrdU-labeled endothelial cells per vascular profile were
measured as described earlier [13,15]. Moreover, sections were double-
stained with antibodies against BrdU and CD68. Sections were first
incubated with the primary antibody for BrdU overnight, followed
by a 30-minute incubation with secondary antibody Envision AP
Mouse (Dako). The sections were developed using Permanent Red
(Dako). The following day, the same sections were incubated with
an antibody against CD68, followed by secondary antibody Envision
HRP Mouse for 30 minutes. The slides were then developed using
diaminobenzidine (Dako).
Apoptosis
Apoptotic tumor cells were identified using a TUNEL assay accord-
ing to the protocol provided by the manufacturer (Roche Diagnostics,
Bromma, Sweden). The percentage of apoptotic cells was determined
in 2000 cells of each tumor examined.
Interleukin 1β and Matrix Metalloproteinase
9 Immunohistochemistry
After microwave heating of paraffin sections in 0.01Mcitrate buffer
pH 6.0 or target 1 antigen retrieval solution (Dako), respectively,
the sections were incubated with antibodies against interleukin
1β (IL-1β diluted at 1:1000; Catalog no. AF-501-NA; R&D Sys-
tems, Minneapolis, MN) or matrix metalloproteinase 9 (MMP-9 di-
luted at 1:100; Catalog no. Sc-6840; Santa Cruz Biotechnology,
Santa Cruz, CA) overnight. The sections were processed using a Vec-
tastain, Elite ABC kit (Vector, Burlingame, CA) or an LSAB kit
(Dako), respectively.
Stereology
The volume density of tumor tissue was determined on hematoxylin-
eosin–stained sections as previously described [9,13,15]. Total tumor
weight was then estimated by multiplying the volume density with
prostate weight.
Targeting TAMs Using Clodronate-Liposomes
Macrophage infiltration to the tumor was suppressed by eliminat-
ing circulating phagocytic cells by intraperitoneal (i.p.) injections
of dichloromethylene-bisphosphonate (clodronate) liposomes. clod-
ronate was a gift from Roche Diagnostics GmbH (Mannheim,
Germany) and was incorporated into liposomes as previously de-
scribed [11]. Clodronate-liposomes (1 ml/100-g body weight, n = 8)
were administered every second day starting 4 days before AT-1 tumor
cell injection. Equal phosphate-buffered saline (PBS) injections (n =
8) were used as appropriate controls in recommendations [11]. AT-1
tumor cells were injected into the ventral prostate of Copenhagen rats
as described; animals were killed 10 days later and tissues were pre-
pared for morphologic analysis as described.
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RNA Preparation, RT2 Profiler PCR Arrays, and Real-time
Quantitative Reverse Transcription–Polymerase Chain Reaction
RNA, from tumors, ventral prostate tissues, and AT-1 cells, was
extracted using the TRIzol method (Invitrogen, Stockholm, Sweden)
following manufacturer’s instructions.
For polymerase chain reaction (PCR) array studies, AT-1 tumor
tissue (n = 11) was compared with normal ventral prostate from
sham-injected animals (n = 10) and with AT-1 cells in vitro (n = 3
different cell batches). Total RNA, isolated from the individual ani-
mals in each group, was pooled together andDNase-treated (DNAse I;
Sigma-Aldrich) to remove contaminating DNA. Complementary
DNA was synthesized on 1 μg of total DNase-treated RNA using
RT2 Profiler PCR array first strand kit C-02 (SABiosciences, by way
of MedProbe, Lund, Sweden) according to protocol. RT2 Profiler
PCR arrays, rat angiogenesis (Catalog no. APRN-024A; SABiosci-
ences), and rat chemokines (Catalog no. PARN-022A; SABiosciences),
were performed according to the manufacturer’s instructions using
the ABI Prism 7900 HT instrument (Applied Biosystems, Foster City,
CA) and ABI Prism 7900 SDS software 2.1. Acquired data were ana-
lyzed with PCR array data analysis template downloaded from the
SuperArray Web site (www.sabioscience.com) and normalized to the
expression level of housekeeping control genes. The specificity of
the SYBR Green assay was confirmed by melting point analysis.
Quantitative reverse transcription–PCR (qRT-PCR) was used to
verify data from the PCR array. Total RNA from individual animal
or AT-1 cells was reverse-transcribed using Superscript II (Invitrogen)
in a 10-μl reaction according to protocol.
Quantification of mRNA levels was performed by real-time qRT-
PCR using the LightCycler SYBR Green I technology (Roche Diag-
nostics, Bromma, Sweden). Reverse transcription–PCR was performed
in a 10-μl reaction volume, using 0.25 μMprimers, 2 to 4 mMMgCl2,
and 2 μl of complementary DNA according to protocol.
The PCR conditions were optimized for each set of primers (Table 1),
and melting curve analysis was performed to confirm specificity.
Negative controls were run in parallel. Data were analyzed using Light-
Cycler analysis software 3.5.3 (Roche Diagnostics, Bromma, Sweden).
Hypoxia Treatment of AT-1 Cells In Vitro
AT-1 cells were grown at 37°C for 6 and 24 hours in a hypoxic in-
cubator (1% O2, 5% CO2, 94% N2; Billups-Rothenberg, San Diego,
CA) or in normoxia (21% O2, 5% CO2, 74% N2). Total RNA was
prepared as described above, and hypoxic AT-1 cells were compared
with normoxic controls using the PCR arrays described.
Statistical Analysis
Values are presented as mean ± SD.Mann-WhitneyU test was used
for comparison between groups. The Spearman’s rho test was used for
Table 1. Oligonucleotides Used as Primers in the Real-time qRT-PCR.
Primer Sequence (5′-3′) Product Size (bp) Annealing Temperature (°C) Accession No.
ANG-1 Sense – GTC GGA GAT GGC CCA G 113 65 NM_053546
Antisense – CTG TGA GCT TTC TGG TC
ANG-2 Sense – CAG CCA ACC AGG AAG TGA TT 76 62 XM_344544
Antisense – GAG CAT CTG GGA ACA CTT GCA
CCL-2 Sense – CTC TTC CTC CAC CAC T 149 60 NM_031530
Antisense – TTG GGA TCA TCT TGC CAG
CSF-1 Sense – CCC TCG GAC ATT GGA T 161 60 NM_023981
Antisense – GGT AGT GGT GGA CGT T
CXCL1 Sense – GAG GCT TGC CTT GAC C 175 60 NM_030845
Antisense – AGG ACC CTC AAT AGA AAT CG
CXCL9 Sense – ATC CCC TAG ACG GTT G 147 60 NM_145672
Antisense – AGT GAC GTG TTT ACT CTG
EGF Sense – CCG TCG TAC GAT GGG T 159 60 NM_012842
Antisense – CCT CTG CCC GTA GTC A
EREG Sense – CCG GTT CCT ACT CAG C 167 60 NM_021689
Antisense – TGA CGG AAT CAC GGT T
FGF-2 Sense – CAC TTA CCG GTC ACG GAA AT 80 60 NM_019305
Antisense – CCG TTT TGG ACT CGA GTT TA
Interferon γ Sense – AGG ACG GTA ACA CGA AA 117 60 NM_138880
Antisense – GGT GCG ATT CGA TGA C
IL-1β Sense – AAA AAT GCC TCG TGC TGT CT 127 60 NM_031512
Antisense – GGG ATT TTG TCG TTG CTT GT
IL-6 Sense – GGA GTG GCT AAG GAC C 164 60 NM_012589
Antisense – AGA TAC CCA TCG ACA GG
MMP-3 Sense – CTT CGA TGC AGT CAG C 214 60 NM_133523
Antisense – ATG ACC TCG GAT AGC C
MMP-9 Sense – TTC GAC GCT GAC AAG AAG TG 156 60 NM_031055
Antisense – AGG GGA GTC CTC GTG GTA GT
PTGS1 Sense – GAC TAC GGT GTC GAG 131 60 NM_017043
Antisense – CGC ATT TCT CGG GAC T
Serpinb5 Sense – ATT CCA TCG AGG TGC C 186 60 NM_057108
Antisense – AGA GCC CTG CAA CTA C
TGFβ1 Sense – GGC TAC CAT GCC AAC TTC TGC CT 199 67 X52498
Antisense – TGT TGG ACA GCT GCT CCA CCT TG
TIMP-3 Sense – GGC CTC AAT TAC CGC T 157 60 NM_012886
Antisense – GGA TGC AGG CGT AGT G
VEGF-A Sense – CGA AGT GGT GAA GTT CAT GGA TGT 74 60 M32977
Antisense – TGG AAG ATG TCC ACC AGG GTC
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the correlation studies. P < .05 was considered significant. Statistical
analysis was performed using the statistical software SPSS 14.0 (SPSS
Inc., Chicago, IL).
Results
Macrophage Density and Vascular Proliferation
in the AT-1 Rat Prostate Tumor Model
When a small number of AT-1 tumor cells were injected to one of
the ventral prostate lobes of syngenic and immunocompetent rats, it
resulted in rapid tumor growth. The average tumor diameter was 2,
5, and 9 mm at days 7, 10, and 14, respectively. In other words, the
tumor diameter grew with 1 mm/day, and the tumor-invasive front
expanded with 0.5 mm/day into the surrounding normal prostate
tissue. Blood vessels, stroma cells, and the extracellular matrix in
the normal tissue adjacent to the expanding tumor thus lay within
the tumor the following day.
We have previously shown that vascular density increase with tu-
mor growth in the tumor and also in the surrounding normal pros-
tate tissue [9]. To understand the mechanisms behind the increased
vascularity and to study if there was an association with macrophages,
we analyzed endothelial cell proliferation (BrdU incorporation into
endothelial cells) and monocyte/macrophage content (CD68-positive
cells) in the tumor and in the extratumoral normal prostate tissue.
The tumor contained a high number of CD68-positive macro-
phages particularly at the invasive zone, here defined as the 0.5-mm
tumor surface region and the 0.5-mm-wide zone of normal tissue
most adjacent to the tumor (Figure 1A). Both average intratumoral
macrophage density and endothelial cell proliferation were higher
than in the extratumoral normal tissue (Table 2). Vascular BrdU label-
ing index in the tumor correlated with tumor size (rs = 0.62, P < .01;
Table 2). Conversely, the average intratumoral macrophage density
inversely correlated to both tumor size (rs = −0.57, P < .05) and intra-
tumoral vascular density (rs = −0.54, P < .05; Table 2).
In the extratumoral normal prostate tissue, the fraction of BrdU-
positive endothelial cells also correlated with extratumoral vessel
density (rs = 0.69, P < .01) demonstrating a production of new
blood vessels (Table 2). Proliferation of endothelial cells in the nor-
mal prostate tissue also correlated with tumor size (rs = 0.66, P <
.01). Interestingly, opposite to macrophage content in the tumor,
average extratumoral macrophage density correlated with tumor size
(rs = 0.84, P < .01), extratumoral vascular density (rs = 0.52, P <
.05), and extratumoral vascular proliferation (rs = 0.89, P < .01).
Double staining of macrophages (CD68) and endothelial prolifera-
tion (BrdU) in the extratumoral normal prostate tissue revealed that
macrophages often were in close contact with proliferating endothe-
lial cells in capillaries and with vascular smooth muscle cells in arte-
rioles and veins (Figure 1A). We therefore quantified BrdU labeling
index in the smooth muscle cell layer in arterioles and venules.
Proliferation in such vessels correlated to both tumor size (rs =
0.86, P < .01) and extratumoral macrophage density (rs = 0.76, P <
.01; Table 2). This shows that vascular growth was not restricted to
capillaries and that macrophages probably are important for growth
of all types of extratumoral blood vessels.
As macrophage density was particularly high at the invasive zone
and low in the central tumor parts, we specifically quantified macro-
phage density in the 0.5-mm tumor-invasive region and found that it
remained high and constant during the period examined (Table 2).
The macrophage-rich border zone subsequently increased with tumor
growth and progressed into the normal prostate. Macrophage density
in the 0.5-mm invasive zone of normal prostate tissue was also particu-
larly high already at 7 days and then remained high during tumor
growth (Table 2). In addition, we also noted that the invasive zone
had the highest vascular BrdU labeling index (data not shown). The
majorities of blood vessels were thus produced and enlarged in the
macrophage-rich border zone and then subsequently incorporated in
the expanding tumor.
Reduction of Macrophages with Clodronate-Liposomes
Inhibited Tumor Growth, Angiogenesis, and Arteriogenesis
To determine the importance of macrophages for AT-1 prostate
tumor growth, rats were depleted of circulating phagocytic cells by
administration of clodronate-liposomes. Peritoneal injections before
and during tumor growth were administrated to reduce the recruit-
ment of macrophages to the injected tumor cells.
In clodronate-liposome–treated rats, AT-1 tumor size was 71%
smaller (P < .01) compared with untreated controls (Figure 1B).
Tumor cell apoptosis (TUNEL), which was similar in the invasive
zone and more central tumor areas, was significantly increased in
the clodronate-liposome–treated animals compared with controls
(0.6 ± 0.2% vs 0.3 ± 0.2%, P < .01; Figure 1C ). Increased apoptosis
was seen both in central and in peripheral parts of the tumors. There
was, however, no increase in apoptosis in the normal ventral prostate
tissue either close to or more remote from the tumor (data not shown).
Tumor cell proliferation was unaffected by clodronate-liposome treat-
ment (data not shown).
To verify macrophage reduction, macrophage density (CD68) was
analyzed in tumors and extratumoral prostate tissues at day 10 after
tumor implantation. In clodronate-liposome–treated animals, macro-
phage density was 40% lower (P < .05) in the tumor and 35% lower
Figure 1. (A) Section from the ventral prostate in an animal injected with AT-1 cells 10 days earlier stained for macrophages (CD68,
brown; original magnification, ×40), microvessels and a larger vessel stained for BrdU (brown; original magnification, ×400), and a
small venule double-stained for proliferation (BrdU, red) and macrophages (CD68, brown) (original magnification, ×400). Note the in-
tense staining of CD68 in the invasive zone and that BrdU labeling is present in endothelial and in vascular smooth muscle cells. Note
also the close contact between proliferating vascular cells and macrophages. (B) Tumor weight, macrophage densities (percentage of
CD68-positive cells), vascular densities (percentage of factor VIII-positive cells), and vascular proliferation (BrdU labeling index) were
significantly inhibited in clodronate-liposome–treated rats (n = 8) compared with PBS controls (n = 8). Values are means ± SD. *P <
.05. **P < .01. (C) Tumors from clodronate-liposome–treated rats and PBS controls stained for tumor apoptosis (TUNEL, brown, arrow-
heads; original magnification, ×400), macrophages (CD68, brown; original magnification, ×40), blood vessels (factor VIII, red; original
magnification, ×100), and proliferation (BrdU, red; original magnification, ×200). Blood vessels (arrowheads) showed decreased BrdU
staining in clodronate-liposome–treated animals compared with controls, whereas no difference in tumor proliferation was noted. (D)
AT-1 tumor-invasive zone stained for MMP-9 (brown; original magnification, ×200) and IL-1β (brown; original magnification, ×400).
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(P < .05) in the extratumoral prostate tissue compared with controls
(Figure 1, B and C ). The liver has previously been shown to be de-
pleted of macrophages by i.v. injections of clodronate-liposomes [16],
and here macrophage density was decreased with 62% (P < .01).
To investigate whether macrophage reduction affected vasculariza-
tion, tumor and extratumoral tissues were analyzed for vascular den-
sity (factor VIII expression) and vascular proliferation (BrdU-positive
endothelial cells). Both vascular density (Figure 1, B and C ) and
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endothelial cell proliferation (Figure 1, B and C ) were significantly
inhibited in the tumor and in adjacent prostate tissue in clodronate-
liposome–treated animals compared with controls. In addition, mac-
rophage reduction resulted in suppressed proliferation of vascular
smooth muscle cells (BrdU labeling index) in large vessels compared
with controls (3.0 ± 2.3 vs 8.4 ± 2.3, P < .01).
Characterization of Angiogenic Factors and Chemokines
Expressed by the Orthotopic AT-1 Tumor
To investigate what factors the AT-1 tumor express, which could
stimulate angiogenesis and monocyte/macrophage recruitment, we
used a rat angiogenesis and a rat chemokine PCR array. The ortho-
topic tumor in vivo was compared with normal prostate control tissue
and with AT-1 tumor cells in vitro.
The results showed that the tumor produced numerous angiogenic
factors: 28 of 75 examined factors were upregulated and 17 were
downregulated in the tumor tissue compared with normal prostate
controls (Table 3). In addition, 18 factors were verified with qRT-
PCR and were all significantly changed compared with normal pros-
tate tissue (Table 3). Proangiogenic factors, such as fibroblast growth
factor 2 (FGF-2), angiopoietins 1 and 2 (ANG-1 and ANG-2), trans-
forming growth factor β (TGFβ), and vascular endothelial growth
factor (VEGF), were mainly elevated, whereas antiangiogenic factors,
such as Serine proteinase inhibitor b5 (Serpin-b5; also called Maspin),
tissue inhibitor of metalloproteinase 3 (TIMP-3), thrombospondin 4,
and brain-specific angiogenesis inhibitor 1 were decreased. Matrix
metalloproteinases 3, 9, and 19, central for extracellular matrix deg-
radation, were also highly increased in the tumor (Table 3).
To determine whether some of these factors could be produced
by macrophages, we compared the orthotopic AT-1 tumor at day
10 with AT-1 cells in vitro. Of the 28 angiogenesis factors upregu-
lated compared with normal prostate control tissue, 12 were highly in-
creased in vivo, suggesting that macrophages or other nonmalignant
cells could contribute to their production (Table 3). Several of these
factors have been shown to be produced by macrophages (for reviews,
see [5,17]), and staining of MMP-9 and IL-1β in the tumors showed
that both these proteins were located in macrophage-like cells, par-
ticularly at the invasive border. Tumor cells, however, were unstained
(Figure 1D).
The most important chemokines for monocyte recruitment to tu-
mors seem to be CCL-2, colony-stimulating factor 1 (CSF-1), and
VEGF (for review, see [1]). The chemokine array revealed that
the AT-1 tumor expressed both CCL-2 and CSF-1 and several other
chemokines in addition (Table 4). mRNA expressions of CCL-2,
CSF-1, and VEGF were also verified with qRT-PCR and were all
significantly increased in vivo compared with normal prostate control
tissue (Figure 2). Both CSF-1 and VEGF were highly expressed by
AT-1 tumor cells in vitro compared with normal prostate control tis-
sue, whereas CCL-2 had low expression in vitro (Figure 2). Vascular
endothelial growth factor and CCL-2 had significantly increased
mRNA expressions in the AT-1 tumor in vivo compared with AT-1
cells in vitro.
Various studies have shown that hypoxia can upregulate both angio-
genic factors and chemokines (for review, see [18]). Because large parts
of our AT-1 tumors are hypoxic [9], we examined whether hypoxia
could explain why some factors are increased in AT-1 tumors in vivo
compared with AT-1 cells in vitro. To test this, AT-1 cells in vitro were
incubated up to 24 hours in hypoxia and compared with normoxic
controls using the same arrays. The results showed no major differ-
ences in angiogenic or chemotactic profiles between hypoxic and nor-
moxic AT-1 cells in vitro (data not shown) compared with the major
changes seen when comparing AT-1 tumors in vivo versus AT-1 cells
in vitro. For example, CSF-1, VEGF, ANG-2, CCL-2, IL-1β, TGFβ,
and MMP-9 expressions were only marginally affected, and FGF-2
decreased by hypoxia in vitro.
Discussion
In this study, we observed that macrophages were present in high
numbers in rat prostate tumors, particularly at the invasive zone but
importantly also in the extratumoral normal prostate tissue. In addi-
tion, we showed that the tumor expressed numerous factors that stim-
ulate monocyte recruitment, angiogenesis, and tissue remodeling.
Furthermore, a reduction of monocytes/macrophages to the tumor
and its surroundings with clodronate-liposomes resulted in inhibited
tumor growth and repressed intratumoral and extratumoral angiogen-
esis and arteriogenesis.
Studies of macrophage infiltration to human prostate cancer have
shown diverse results with both positive and negative associations to
clinical outcome and cancer progression [6,7]. Interestingly, TAMs in
different tumor compartments apparently have opposing effects on
prostate cancer progression [6,7]. Two different polarization states
have been described for macrophages: the M1 phenotype has anti-
tumoral effects, whereas the M2 macrophage promotes angiogenesis,
tumor growth, and metastasis [19]. Tumor-associated macrophages
Table 2. Quantitative Analysis of Intratumoral and Extratumoral Vascular Density, Vascular Proliferation, and Macrophage Density.
Days Vascular Density Factor VIII (%) Vascular Proliferation BrdU (Labeling Index) Macrophage Density CD68 (%)
Total Large Vessels Total Invasive Zone
Intratumoral
7 2.5 (0.29) 25.6 (10.5) ND 5.0 (0.67) 8.1 (1.0)
10 3.6 (0.82)* 35.9 (12.0) ND 4.8 (0.62) 8.0 (1.5)
14 4.6 (1.49)* 46.4 (10.8)† ND 3.5 (1.40) 8.9 (1.8)
Extratumoral
7 1.2 (0.27) 5.3 (3.5) 2.5 (6.1) 0.62 (0.18) 3.7 (0.79)
10 1.8 (0.32)* 21.2 (7.5)* 7.1 (6.1) 0.74 (0.16) 3.7 (1.20)
14 2.8 (0.85)* 26.8 (6.3)* 17.1 (4.9)* 1.40 (0.24)* 4.1 (0.94)
Groups of 5 to 16 rats at each time point.
Values are presented as means (SD).
ND indicates not determined.
*P < .01 when compared with day 7.
†P < .05 when compared with day 7.
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Table 3. Angiogenic Factors Altered in the Orthotopic AT-1 Rat Prostate Tumor Compared with Normal Rat Prostate Tissue and with AT-1 Tumor Cells In Vitro Analyzed with PCR array
and qRT-PCR.
Accession No. Symbol Description Fold Up- or Down-regulation
Superarray qRT-PCR
Angiogenic Factors Upregulated in the Orthotopic AT-1 Tumor Compared with Normal Control Tissue
XM_344544 Ang-2 Angiopoietin 2 6.2 4.1 (1.0)*
NM_053546 Ang-1 Angiopoietin 1 14.9 9.4 (3.1)*
NM_031530 CCL2/MCP-1 Chemokine (C-C) ligand 2 15.6 7.1 (2.7)*
XM_241632 Col18a1 Collagen XVIII alpha 1 32.3
NM_022266 CTGRP Connetive tissue growth factor 4.7
NM_030845 CXCL1/Gro1 Chemokine (C-X-C) ligand 1 51.6 4.4 (1.8)*
NM_145672 CXCL9/Mig Chemokine (C-X-C) ligand 9 8.4 5.6 (7.8)*
XM_234903 Efna2 Ephrin A2 3.4
NM_021689 Ereg Epiregulin 164.5 3.3 (0.4)*
NM_019305 Fgf-2/bFGF Fibroblast growth factor 2 23.1 5.3 (1.1)*
NM_019143 Fn-1 Fibronectin 1 32.8
NM_024359 Hif1α Hypoxia inducible factor 1 alpha 3.3
NM_012797 ID125A Inhibitor of DNA binding 1 3.3
NM_138880 IFNγ Interferon gamma 6.1 4.5 (1.8)*
NM_031512 IL1β Interleukin 1 beta 24.0 13.8 (3.2)*
NM_012589 IL6 Interleukin 6 82.3 4.2 (1.2)*
XM_235707 Itga5 Integrin alpha 5 4.4
XM_222317 Mmp19 Matrix metalloproteinase 19 22.2
NM_133523 Mmp3 Matrix metalloproteinase 3 545.0 19.5 (7.1)*
NM_031055 Mmp9 Matrix metalloproteinase 9 32.2 8.9 (2.3)*
NM_012613 Npr1 Natriuretic peptide receptor 1 3.1
NM_145098 Nrp1 Neuropilin 1 15.9
NM_030869 Nrp2 Neuropilin 2 11.4
NM_013085 UPAM Plasminogen activator, urokinase 11.2
NM_017043 Ptgs1/Cox1 Prostaglandin endoperoxide synthase 1 23.8 547.3 (509.3)*
NM_021578 TGFβ Transforming growth factor beta 1 22.5 18.5 (3.2)*
NM_053819 Timp-1 Tissue inhibitor of metalloproteinase 1 5.1
NM_031836 VEGF Vascular endothelial growth factor A 3.7 5.5 (1.4)*
Angiogenic Factors Downregulated in the Orthotopic AT-1 Tumor Compared with Normal Control Tissue
NM_031012 APN Alanyl aminopeptidase −7.9
XM_343260 Bai1 Brain-specific angiogenesis inhibitor 1 −8.2
XM_343607 Col4a3 Collagen IV alpha 3 −21.3
NM_053903 Efna5/Lerk7 Ephrin A5 −29.6
NM_012842 Egf Epidermal growth factor −106.2 −33.9 (14.2)*
NM_023090 Hif2α Endothelial PAS domain protein 1 −3.5
NM_021867 Fgf16 Fibroblast growth factor 16 −5.0
NM_053429 Fgfr3 Fibroblast growth factor receptor 3 −29.1
NM_173838 Fzd5 Frizzled homolog 5 −3.9
NM_013076 OB/obese Leptin −10.2
NM_030859 Mdk Midkine −4.8
NM_031054 Mmp2 Matrix metalloproteinase 2 −4.1
XM_574314 Plg/Ab1-346 Plasminogen −26.9
NM_057108 Serpinb5 Serine proteinase inhibitor 5 −98.3 −9.3 (4.1)*
XM_220811 Tbx4 T-box 4 −11.5
XM_342172 Thbs4 Thrombospondin 4 −4.2
NM_012886 Timp3 Tissue inhibitor of metalloproteinase 3 −6.1 −2.9 (1.5)*
Angiogenic Factors Upregulated in the AT-1 Tumor In Vivo Compared with the AT-1 Cells In Vitro
XM_344544 Ang-2 Angiopoietin 2 22.6 76.6 (17.9)†
NM_031530 CCL2/MCP-1 Chemokine (C-C) ligand 2 55.6 16.7 (6.3) †
XM_241632 Col18a1 Collagen XVIII alpha 1 5.9
NM_145672 CXCL9/Mig Chemokine (C-X-C) ligand 9 98.8 525.8 (729.8)†
XM_234903 Efna2 Ephrin A2 26.5
NM_019305 Fgf-2/bFGF Fibroblast growth factor 2 9.2 5.3 (1.1)†
NM_138880 IFNγ Interferon gamma 6.1 419.9 (164.4)†
NM_031512 IL1β Interleukin 1 beta 501.5 93.2 (21.9)†
NM_031055 Mmp9 Matrix metalloproteinase 9 37.5 17.8 (4.7)†
NM_012613 Npr1 Natriuretic peptide receptor 1 92.8
NM_145098 Nrp1 Neuropilin 1 64.4
NM_021578 TGFβ Transforming growth factor beta 1 7.3 2.9 (0.5)†
For Superarray comparisons, AT-1 tumors (n = 11) were pooled into one sample and compared with pooled normal prostate tissue (n = 10). Quantitative RT-PCR was performed on tumor (n = 11) or
normal prostate tissue (n = 10) from individual animals.
Values are presented as mean (SD).
*P < .01.
†P < .05.
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generally exhibit an M2-like phenotype, although a mixed M1 and
M2 phenotype is also described [19]. In this prostate cancer model,
macrophages in the extratumoral tissue seemed particularly important
for vessel growth, whereas the role of macrophages inside the tumor
was more unclear. We noted that both macrophage density and vascu-
lar proliferation were highest in the tumor-invasive zone where macro-
phages could promote invasion, tissue remodeling, and angiogenesis.
Already existing vessels in the extratumoral tissue may also promote
tumor vascularization through co-option, a process where existing ves-
sels are surrounded by tumor cells and used to supply the tumor [20].
Furthermore, macrophages infiltrating the extratumoral tissue were of-
ten seen in close contact with proliferating endothelial cells in capillar-
ies and with smooth muscle cells in arterioles and venules. Reduced
macrophage infiltration resulted in repressed proliferation in capillaries
and in large vessels, and macrophages therefore seem to have a central
role in both angiogenesis and arteriogenesis in this tumor model. Al-
most all studies on TAMs explore their roles within tumors, and their
roles in the surrounding nonmalignant tissue and particularly for tu-
mor-related arteriogenesis have surprisingly not been examined [17].
However, as macrophages play an important role for the arteriogenesis
and collateral artery growth in ischemia [21,22], we suggest that they
are probably also important for the expansion of larger vessels in the
normal tissue surrounding tumors. Previous studies have shown that
inhibiting the macrophage chemoattractant CCL-2 in a subcutaneous
prostate xenograft model in nude mice reduced macrophage influx, in-
tratumoral angiogenesis, and tumor growth [8]. In a subcutaneous rat
Table 4. Chemokines Altered in the Orthotopic AT-1 Rat Prostate Tumor Compared with Normal Rat Prostate Tissue Analyzed with PCR array.
Accession No. Symbol Description Fold Up- or Down-regulation
Chemokines Upregulated in the Orthotopic AT-1 Tumor Compared with Normal Control Tissue
NM_012513 Bdnf Brain-derived neurotrophic factor 12.2
NM_053303 Blr1/NLR Burkitt lymphoma receptor 1 3.3
XM_213425 Ccl12 Chemokine (C-C) ligand 12 8.1
NM_031530 Ccl2 Chemokine (C-C) ligand 2 4.1
NM_020542 Ccr1 Chemokine (C-C) receptor 1 3.3
XM_226200 Cmtm3/Cklfsf3 CKLF-like MARVEL 4.1
NM_023981 Csf1 Colony-stimulating factor 1 3.5
NM_133534 Cx3cr1 Chemokine (C-X3-C) receptor 1 6.3
NM_030845 Cxcl1/Gro1 Chemokine (C-X-C) ligand 1 7.9
NM_053647 Cxcl2/Mip-2 Chemokine (C-X-C) ligand 2 3.7
NM_022214 Cxcl5 Chemokine (C-X-C) ligand 5 18.5
NM_153721 Cxcl7/Nap-2 Chemokine (C-X-C) ligand 7 7.5
NM_022205 Cxcr4 Chemokine (C-X-C) receptor 4 6.8
NM_0010037 Grp77/C5L2 G protein–coupled receptor 77 5.9
NM_019165 IL18 Interleukin 18 4.5
NM_017183 IL8rβ Interleukin 8 receptor beta 4.5
XM_344130 Lnhβb Inhibin beta-B 3.1
NM_019340 Rgs3 Regulator of G-protein signaling 3 3.3
Chemokines Downregulated in the Orthotopic AT-1 Tumor Compared with Normal Control Tissue
NM_013107 Bmp6 Bone morphogenetic protein 6 −4.3
XM_342421 C5 Similar to complement 5 −3.2
NM_078621 Ccbp2/D6 Chemokine binding protein 2 −8.3
XM_342824 Ccl19 Chemokine (C-C) ligand 19 −3.3
NM_019233 Ccl20 Chemokine (C-C) ligand 20 −3.7
XM_236658 Ccrl2 Chemokine (C-C) receptor-like 2 −6.7
NM_053352 Cmkor1 Chemokine orphan receptor 1 −4.0
NM_134455 Cx3cl1 Chemokine (C-X3-C) ligand 1 −36.5
NM_053415 Cxcr3 Chemokine (C-X-C) receptor 3 −12.4
NM_012590 Inha Inhibin alpha −3.1
NM_031054 Mmp2 Matrix metalloproteinase 2 −5.7
NM_033098 Tapbp/Tapasin TAP binding protein −4.4
For Superarray comparisons, AT-1 tumors (n = 11) were pooled into one sample and compared with pooled normal prostate tissue (n = 10).
Figure 2.Monocyte chemoattractant protein 1 (CCL-2), CSF-1, and
VEGF mRNA expressions in AT-1 prostate tumor cells in vitro (n =
3 different batches) and AT-1 prostate tumors in vivo (n = 11)
quantified with qRT-PCR and expressed in relation to levels in nor-
mal rat prostate tissue (n = 10). Values are means ± SD: *P < .05,
**P < .01.
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prostate tumor model, treatment with an antiangiogenic agent also in-
hibited macrophage function and impaired tumor growth [23]. Agents
used in the earlier studies have, beside the effects onmacrophages, direct
effects on both tumor and endothelial cells. To reduce macrophage in-
filtration, we used intraperitoneal injections of clodronate-liposomes,
which are phagocytosed by, and induce apoptosis in circulating phago-
cytic cells [11]. This method has been used to deplete macrophages and
thereby to reduce angiogenesis and tumor growth in a variety of tumor
models [24–26]. In some models such as glioma, depletion of macro-
phages, however, resulted in increased tumor growth, although a small
reduction in vessel density was observed [27]. Because the concentration
of free clodronate in the prostate is unknown in this experimental setup,
some of the effects seen might be due to direct effects of clodronate on
tumor and endothelial cells. Direct effects are, however, most likely mi-
nor because clodronate-liposomes cannot cross-vascular barriers, and
free clodronate released from dead phagocytic cells have a very short
half-life in the circulation [11]. Monocytes/macrophages that have
phagocytosed clodronate-liposomes could also be inhibited in their nor-
mal functions. Circulating monocytes have been shown to be depleted,
but as new monocytes are constantly entering the circulation from the
bone marrow, a continuous supply of clodronate-liposomes is needed to
inhibit macrophage recruitment [28]. This probably explains why tu-
mors from clodronate-liposome–treated animals contained CD68-
positive cells at day 10 (2 days after the last liposome injection). Notably,
although the reduction in macrophage densities in tumor and extratu-
moral tissues was modest, we observed a significant inhibition in tumor
growth, suggesting that only a moderate decline in macrophage infiltra-
tion is sufficient. Together, our report and a previous report [8,23]
strongly suggest the importance of macrophages for prostate cancer
growth and angiogenesis. The specific effects of macrophage depletion
during various phases of prostate tumor development and metastasis,
however, need to be examined further.
Prostate tumor growth is angiogenesis-dependent, and the ortho-
topic rat prostate tumors expressed numerous factors important for an-
giogenesis. Several of these factors are apparently produced by tumor
cells, whereas others are produced by host cells. Some of the factors
produced, for example, VEGF, TGFβ, and ANG-2, have already
been reported to be of major significance for angiogenesis in prostate
cancer [29,30]. Macrophages could be the source of many of the an-
giogenic factors because expressions of these factors, for example,
CCL-2, IL-1β, FGF-2, TGFβ, and MMP-9, were highly increased
in the tumor in vivo compared with the tumor cells in vitro. To support
this, MMP-9 and IL-1β staining was found in macrophages in the
invasive zone. Matrix metalloproteinases, and MMP-9 in particular,
are important for tissue remodeling and facilitate tumor growth, mi-
gration, invasion, and angiogenesis (for review, see [31,32]). Matrix
metalloproteinase 9 could thus be a key factor produced by macro-
phages in our tumor model. Interleukin 1β has been shown to alter
androgen receptor function [33] and promote tumor invasiveness
and angiogenesis in prostate, breast, and melanoma tumor models
[34]. Macrophage accumulation in the normal tissue adjacent to tu-
mors could thus explain why this tissue shows an altered early response
to castration [9]. It is also possible that factors upregulated in tumors
in vivo versus in vitro are produced by tumor cells. Hypoxia (chronic or
intermittent) and other environmental factors in the prostate in vivo
may alter their expression profile. We could, however, not observe any
major differences between cells exposed to hypoxia for 24 hours and
controls at the mRNA level. Although this finding does not exclude
the possibility that the local environment may alter expression in
tumor cells, it suggests that the most likely reason to the large differ-
ences in expression profiles between tumors in vivo and tumor cells
in vitro is expression in host cells.
Our clodronate-liposome–treated animals (examined 2 days after
last injection) were unfortunately not suitable to prove macrophage
versus tumor cell expressions of these factors because the reduction in
tumor macrophage content was incomplete.
If macrophages are important for prostate tumor growth, it is im-
portant to elucidate the factors responsible for the macrophage accu-
mulation. Chemokine (C-C) ligand 2, CSF-1, and VEGF are all
important for monocyte recruitment to tumors [1] and, together
with other chemokines, were highly expressed by the AT-1 tumor
in vivo. Colony-stimulating factor 1 and VEGF were also expressed
in vitro suggesting that AT-1 cells attract macrophages by secreting
these factors, and that macrophages arriving to the tumor enhance
this process by secreting CCL-2 and VEGF. This suggests that inhi-
bition of several chemotactic factors simultaneously might be needed
to reduce macrophage infiltration.
In summary, macrophages accumulating in the normal tissue sur-
rounding tumors could be one important source of angiogenic and
arteriogenic factors in prostate cancer and decreasing macrophages
could be used as an antivascular/antitumor treatment. Decreasing
macrophages could also inhibit tissue remodeling and tumor invasion
into the surrounding normal tissue by reducing the levels of MMP-9
and IL-1β. Nevertheless, combinatorial therapies directed against
both tumor and nonmalignant cells and neutralizing many of the in-
dividual factors involved are probably needed to get a pronounced
and sustained effect on tumor growth. Further studies are needed
to test this hypothesis.
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